INTRODUCTION {#s1}
============

Mutations in the tumor necrosis factor receptor-associated factor NF-κB activator (TANK)-binding kinase 1 (*TBK1*) gene, located on Chromosome 12, have recently been described as a cause of familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) ([@MCS003913LAMC6]; [@MCS003913LAMC9]; [@MCS003913LAMC23]). Patients have usually presented with either behavioral variant FTD, pure ALS, or a combination of both (FTD--ALS), and multiple different syndromes have been observed within the same family ([@MCS003913LAMC27]).

TBK1 is a 729-amino acid protein kinase that acts as a mediator of inflammation and autophagy ([@MCS003913LAMC19]; [@MCS003913LAMC1]). It is a ubiquitously expressed serine--threonine kinase belonging to the "noncanonical IκB kinases" (IKKs) ([@MCS003913LAMC19]; [@MCS003913LAMC1]). More than 40 mutations have been found in the *TBK1* gene that cause either a frameshift or a premature stop codon, likely leading to a truncated or absent protein product ([@MCS003913LAMC10]). Similar to mutations in the progranulin (*GRN*) gene, these are likely to be pathogenic through haploinsufficiency ([@MCS003913LAMC9]). More than 50 missense mutations have also been described with unclear pathogenicity ([@MCS003913LAMC10]). Further functional work will be required to assess whether these are truly pathogenic or could represent risk factors for FTD and ALS.

Corticobasal syndrome (CBS) is a rare neurodegenerative disease characterized by progressive asymmetrical rigidity and apraxia ([@MCS003913LAMC3]). Other features include myoclonus, akinesia, dystonia, alien limb phenomena, and cognitive impairment. CBS is pathologically heterogeneous with only around half of cases being associated with the typical histological findings of corticobasal degeneration ([@MCS003913LAMC18]). Other cases are caused by progressive supranuclear palsy, Alzheimer\'s disease, and, more rarely, TDP-43 pathology. The majority of cases of CBS are sporadic but familial cases have been rarely described in association with mutations in *GRN*, microtubule-associated protein tau (*MAPT*), Chromosome 9 open reading frame 72 (*C9orf72*), and colony-stimulating factor 1 receptor (*CSF1R*) ([@MCS003913LAMC21]; [@MCS003913LAMC24]; [@MCS003913LAMC2]).

In this report, we describe the clinical, radiological, and pathological features of a 59-yr-old woman who developed CBS in association with primary progressive aphasia caused by a novel *TBK1* mutation.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

A right-handed woman presented at the age of 59 with a 6-mo history of progressive speech problems. Her initial symptoms were of knowing what she wanted to say but not being able to get the words out. There were no other cognitive, behavioral, or motor symptoms. Her symptoms slowly progressed over the next 2 yr and when assessed at the age of 62, her problems continued to be of impaired speech output without any other cognitive symptoms. Cranial nerve and limb neurological examinations were normal, but she had a reduced score of 81/100 on the Addenbrooke\'s Cognitive Examination (subscores: 18/18 attention and orientation, 20/26 memory, 7/14 fluency, 24/26 language, and 12/16 visuospatial). Formal psychometric testing was not performed but she was assessed on the Boston Naming Test, where she scored within the normal range (57/60). Blood tests and CSF examination were normal, as was electromyography. However, an MRI brain scan was abnormal, showing focal right frontal lobe atrophy ([Fig. 1](#MCS003913LAMF1){ref-type="fig"}; [Supplemental Movie S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003913/-/DC1)). A diagnosis of PNFA was made.

![Magnetic resonance imaging scans demonstrating frontal lobe atrophy, with the right side more markedly affected. (*Top*) T1-weighted sagittal views. (*Bottom*) T2-weighted axial (*left*) and coronal (*middle* and *right*) views.](MCS003913Lam_F1){#MCS003913LAMF1}

Neither of her parents had a neurodegenerative illness, but her father died of myocardial infarction in his 40s. The mother died aged 83 of a stroke. She was one of seven siblings: One sister developed a rapidly progressive dementia in her 60s (II.2), two other sisters were diagnosed with ALS in their 40s (II.3) and 60s (II.4), and another sister was thought to have ALS and dementia with onset in her 50s (II.6), highlighting the variability of clinical presentations within the same family ([Fig. 2](#MCS003913LAMF2){ref-type="fig"}A). II.2 first developed symptoms aged 65, presenting with a change in behavior. She became childlike in her demeanor and exhibited changes in appetite, developing a very sweet tooth and tending to overfill her mouth. Her behavior decline was rapid, deteriorating over a period of 6 mo. She was diagnosed with dementia and died aged 68. II.3 first developed symptoms aged 39 and was reported to have difficulties with her speech and swallowing, which progressed rapidly over a period of 3 mo; she was not reported to have any cognitive or behavioral difficulties. She was diagnosed with ALS and died aged 48. II.4 developed symptoms aged 59 and was diagnosed with ALS; however, she was not reported to have any difficulties with her speech or swallowing. Her symptoms progressed over a period of 12 mo. She died aged 69. II.6 developed symptoms aged 60. She was thought to have ALS and memory problems, but little was known of her condition as she reportedly became a recluse, refusing to leave the house or let anyone visit her. She died aged 68.

![(*A*) Pedigree indicating the diversity of familial neurological disease present among family members. (*B*) Structure of the *TBK1* gene (NM_013254) and reserve-complement chromatogram showing the position of the c.2107G\>T variant identified in the index case (II.7), leading to a 27-amino acid deletion in the CC2 domain of the TBK1 protein. (AAD) Age at death, (AAO) age at onset, (S/T) serine-threonine, (UbLD) ubiquitin-like domain, (CC1) coiled-coil domain 1, (CC2) coiled-coil domain 2.](MCS003913Lam_F2){#MCS003913LAMF2}

The patient\'s speech problems progressed and, when reassessed 4 yr into her illness, she had minimal speech output with evidence of orofacial apraxia. She had developed impaired swallowing and had had a PEG tube inserted. She had also developed an asymmetric akinetic--rigid syndrome with apraxia, dystonia, and myoclonus, affecting the left arm and, to a lesser extent, the left leg more than the right side. She also had difficulty initiating saccadic eye movements. Repeat electromyography of the four limbs was normal. A diagnosis of CBS was made.

She continued to progress over the next few years with worsening comprehension of speech and increasing difficulty with movement. By 8 yr into the illness, she became dependent on nursing care for all her personal care needs and was not assessed further following this. Although not formally assessed, the cognitive impairment at this stage was of sufficient severity to significantly interfere with activities of daily living and contributed to her loss of independence. She died from bronchopneumonia at the age of 71, after a progressive neurodegenerative illness lasting 12 yr in duration.

The patient consented to brain donation, and after death her brain was assessed using standard neuropathological methods at the Queen Square Brain Bank, where tissue is stored for research under a licence from the UK Human Tissue Authority. Representative areas of neocortex, basal ganglia, hippocampus, midbrain, pons, medulla, and cerebellum were examined using routine stains, with additional immunohistochemical staining for Aβ, tau (AT8), TDP-43, ubiquitin, p62, GFAP, CD68, and α-synuclein. Macroscopic examination showed marked atrophy of the frontal and parietal lobes and, to a lesser extent, atrophy of the temporal lobe with severe dilatation of the lateral ventricle. There was severe atrophy of the amygdala with moderate atrophy of the hippocampus. The caudate and globus pallidus were also atrophic and there was marked pallor of the substantia nigra and locus coeruleus ([Fig. 3](#MCS003913LAMF3){ref-type="fig"}). Histological examination of the left hemisphere showed marked cortical pathology with thinning, neuronal loss, and spongiosis, most severe in the frontal and parietal lobes. There was neuronal loss and gliosis in the caudate and globus pallidus, and this was severe in the substantia nigra. TDP-43 immunohistochemistry demonstrated short neurites and neuronal cytoplasmic inclusions corresponding to cortical pathology characteristic in the FTLD--TDP type A subtype. Immunohistochemical staining for hyperphosphorylated tau showed features of argyrophilic grains with neurofibrillary tangles in the hippocampus accompanied by grains in the hippocampal CA1 subregion and the subiculum, in addition to small numbers of bushy astrocytes in cortical regions. There was no Aβ or α-synuclein pathology. The right hemisphere was not available for immunohistochemistry, as it was snap-frozen for molecular analysis.

![(*A*) A coronal slice from the left cerebral hemisphere demonstrates ventricular dilatation with atrophy of the frontal lobe, caudate nucleus, and amygdala. In the midbrain, there is severe pallor of the substantia nigra (arrows). (*B*) Histological examination of the frontal lobe by hematoxylin and eosin staining shows thinning and spongiosis of the cortex. (*C*) Severe loss of pigmented neurons in the substantia nigra is confirmed with residual free neuromelanin in the neuropil (arrow and *inset*). (*D*) TDP-43 immunohistochemistry in the frontal lobe shows neurons with loss of the normal nuclear staining pattern and containing cytoplasmic inclusions (arrows and *inset*), in addition to scattered short neurites (arrowheads). (*E,F*) Argyrophilic grains in the subiculum are highlighted by immunohistochemistry for p62 (*E*) and four-repeat tau isoforms (*F*). Scale bar, 300 µm (*B*), 120 µm (*C*), 30 µm (*C inset*, *D*,*E*,*F*), and 20 µm (*D inset*).](MCS003913Lam_F3){#MCS003913LAMF3}

Genomic Analysis {#s2b}
----------------

Genetic screening excluded mutations in *GRN* and *MAPT* (exons 1 and 9--13). Hexanucleotide repeat expansions in the *C9orf72* gene, a cause of familial FTD and/or ALS ([@MCS003913LAMC7]; [@MCS003913LAMC25]), were also excluded. Exome sequencing was undertaken to identify potential pathogenic variants. The patient was found to harbor a novel c.2107G\>T (p.E703X: NM_013254.4) variant in exon 20 of the *TBK1* gene ([Table 1](#MCS003913LAMTB1){ref-type="table"}; [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003913/-/DC1)). Sanger sequencing of exon 20 confirmed the presence of a heterozygous G\>T substitution at nucleotide 2107 ([Fig. 2](#MCS003913LAMF2){ref-type="fig"}B). This variant was not seen in more than 138,000 unrelated exome and genome sequences from the gnomAD database (0/138,632; <http://gnomad.broadinstititue.org/>). This nonsense variant was located in the carboxy-terminal coiled-coil domain 2 (CC2) and results in a premature stop codon, leading to a predicted truncated protein product. Segregation of the variant could not be verified because of the unavailability of blood samples from additional family members.

###### 

Details of variant

  Gene     Chromosome   HGVS DNA reference        HGVS protein reference   Variant type       Predicted effect       dbSNP/dbVar ID     ClinVar ID      Genotype
  -------- ------------ ------------------------- ------------------------ ------------------ ---------------------- ---------------- -------------- --------------
  *TBK1*   12q14.2      NM_013254.4: c.2107G\>T   NP_037386.1: p.E703X     Nonsense variant   Premature STOP codon   Not available     SCV000886403   Heterozygous

DISCUSSION {#s3}
==========

Here, we describe the presence of a novel *TBK1* mutation in a patient who presented clinically with a CBS--PNFA overlap syndrome, radiologically with asymmetric frontal lobe atrophy, and with FTLD--TDP type A pathology at postmortem examination of brain tissue.

Although we did not have access to blood samples to test segregation of the mutation within the family, this variant is highly likely to be pathogenic, as it results in a premature stop codon, and hence a truncated protein product. Heterozygous loss of function variants have been shown to be enriched in familial FTD--ALS pedigrees and are likely to be pathogenic through nonsense-mediated mRNA decay (NMD) and global reduction of protein levels ([@MCS003913LAMC6]; [@MCS003913LAMC9]; [@MCS003913LAMC23]). However, NMD associated with the heterozygous p.E703X mutation described here is unlikely, because of the position of the premature stop codon in the gene ([@MCS003913LAMC12]). Instead, loss of the crucial highly conserved CC2 protein domain is likely to result in the abrogation of the interaction and complex formation with TBK1-associated adaptors that are essential in regulating TBK1 activation and its subcellular localization ([@MCS003913LAMC11]). Mutations within this domain have been shown to disrupt the TBK1/OPTN (optineurin) interaction ([@MCS003913LAMC9]). OPTN is an important autophagy receptor critical for the degradation and clearance of intracellular pathogens, protein aggregates, and damaged organelles. The carboxy-terminal domain of TBK1 binds to the amino-terminal region of OPTN to form the TBK1/OPTN complex ([@MCS003913LAMC17]). TBK1 is also thought to directly phosphorylate OPTN to promote autophagy. Mutations in both the carboxy-terminal domain of TBK1 and the amino-terminal domain of OPTN have been implicated in ALS and other neurodegenerative diseases ([@MCS003913LAMC20]; [@MCS003913LAMC23]), and it is likely that disruption of the formation of the TBK1/OPTN complex impairs critical autophagy processes that are vital to maintaining cellular homeostasis ([@MCS003913LAMC17]). Interestingly, TBK1 has also been shown to act on a common pathway with C9orf72 complexes to regulate autophagy in neuronal cells ([@MCS003913LAMC26]). It was found that by promoting the phosphorylation of one of the proteins in this complex (SMCR8), TBK1 is important for C9orf72-mediated autophagy, thus providing another mechanism by which TBK1 mutations could lead to neurodegeneration. Disruption in autophagy processes has been implicated in other neurodegenerative conditions such as Parkinson\'s disease, in which mutations in *PINK1* and *Parkin* are believed to function in a common pathway to promote defective mitochondrial clearance via autophagy ([@MCS003913LAMC4]).

Clinically, this patient developed an overlap syndrome of primary progressive aphasia (PNFA) followed by CBS. This is a well-described overlap of neurodegenerative syndromes, but only one other case has been described in association with a *TBK1* frameshift mutation ([@MCS003913LAMC5]). Neuroanatomically, there are few reports of the imaging features of *TBK1*-associated disease. Patterns of atrophy are variable and likely reflect the areas most affected by neurodegeneration. In most cases, atrophy is asymmetric and predominantly involves the temporal lobe ([@MCS003913LAMC5]; [@MCS003913LAMC14]). However, atrophy that predominantly affects the frontal cortex, mesencephalon, and cerebellum have all been described, and it is plausible that atrophy patterns correlate with the main clinical phenotype ([@MCS003913LAMC31]). The neuropathological features associated with *TBK1* mutations have also been described infrequently. Most cases reported so far had TDP-43 type B pathology ([@MCS003913LAMC9]; [@MCS003913LAMC23]; [@MCS003913LAMC27]), but TDP-43 type A pathology has also been described ([@MCS003913LAMC23]; [@MCS003913LAMC15]). Whether there is a correlation between mutation type and/or location within the different TBK1 domains and the pathological consequences remains to be elucidated. Of interest, this case also had tau-positive argyrophilic grains, as previously reported, raising the possibility that this additional pathology might be a feature of the disease ([@MCS003913LAMC15]).

Mutations in *TBK1* are the fourth most common cause of familial FTD, and the second most common cause of a combined FTD--ALS syndrome ([@MCS003913LAMC8]). More recently, *TBK1* mutations have been found in patients with progressive supranuclear palsy and progressive cerebellar ataxia syndromes, expanding the phenotypic spectrum of *TBK1*-associated disease ([@MCS003913LAMC31]). Only one other case of familial CBS--PNFA overlap syndrome has been reported in the literature thus far, carrying a frameshift mutation (p.Thr156ArgfsX6) affecting the kinase domain of TBK1 ([@MCS003913LAMC5]). The first described cause of familial CBS was due to a mutation in the *MAPT* gene ([@MCS003913LAMC21]), but this is relatively rare ([@MCS003913LAMC28]) and tends to cause a syndrome with prominent behavioral symptoms. A familial CBS overlap with primary progressive aphasia is more commonly associated with *GRN* mutations ([@MCS003913LAMC29]), but is nonetheless a rare phenotype of *GRN*. More recently, case reports of familial CBS caused by *C9orf72* and *CSF1R* have been described, but this is also rare and an unusual phenotype for these genes. It is increasingly recognized that neurodegenerative disorders are pathologically and genetically heterogeneous. Similar clinical syndromes can have multiple underlying pathologies and genetic cause, and mutations in a single gene can manifest with diverse clinical phenotypes, often in the same kindred. In this context, clearly exemplified by this case report, the exact definition of a clinicopathological entity is increasingly reliant on a genetic diagnosis.

In summary, we describe a novel *TBK1* mutation in a patient who presented with a CBS--PNFA overlap and who had a family history of dementia and ALS. The presence of a family history in a patient with CBS should lead to testing for mutations in the known FTD genes. However, if these are negative sequencing for mutations in *TBK1* should be considered. This case highlights the importance of genetic exome sequencing as a diagnostic tool in patients presenting with CBS and associated neurodegenerative disorders.

METHODS {#s4}
=======

Briefly, for whole-exome sequencing, the sample library was prepared using Illumina Nextera Rapid Capture kits with paired-end sequencing performed using the Illumina HiSeq2000 (Illumina). The sample was sequenced to an average coverage of 39.42 reads with a mean read length of 177.23 bp ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003913/-/DC1)). All reads were subsequently aligned using BWA ([@MCS003913LAMC16]) against UCSC hg19 reference genome. Variant calling and quality-based filtering for all samples were done using GATK ([@MCS003913LAMC22]). Variants were annotated with ANNOVAR ([@MCS003913LAMC30]) with allele frequency data from the gnomAD browser, as well as with predicted impact of variants ([@MCS003913LAMC13]).

For Sanger sequencing, exon 20 was amplified using specific primers (F 5′-CAGCTTCCAGTGGAATCAAACA-3′ and R 5′-AGGCATCACAGATACACAATCA-3′). The amplified PCR product was enzymatically cleaned up and sequenced on both strands using a BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems). Sequencing products were run on a 3730 DNA Analyser (Applied Biosystems) and analyzed using Sequencher DNA Sequence Analysis software (Gene Codes Corp.).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
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Raw sequencing data were not deposited but are available from the authors. The variant described in this study was submitted to ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession number SCV000886403.
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